FDA links once-promising pain drugs to bone decay

WASHINGTON (AP) -- Some of the world's largest drugmakers will face an uphill battle next week in their bid to revive a class of experimental arthritis drugs that have been sidelined by safety concerns for nearly two years....

View the full article